Objective To assess the association between prophylactic indomethacin and bronchopulmonary dysplasia (BPD) in a recent, large cohort of extremely preterm infants.
Conclusions Prophylactic indomethacin was not associated with either reduced or increased risk for BPD or death. (J Pediatr 2017; 186:34-40) .
Trial registration ClinicalTrials.gov: NCT00063063
See editorial, p 11 T he use of prophylactic indomethacin in preterm infants remains controversial. 1 Prophylactic indomethacin reduces the incidence of severe intraventricular hemorrhage and subsequent symptomatic patent ductus arteriosus (PDA). 2 However, prophylactic indomethacin has not been shown to prevent bronchopulmonary dysplasia (BPD), despite a strong association between PDA and the development of BPD. [2] [3] [4] [5] [6] [7] The available data from randomized trials are consistent with the hypothesis that prophylactic indomethacin may adversely affect respiratory outcomes. The most recent Cochrane Review on prophylactic indomethacin included 9 RCTs that assessed supplemental oxygen use at 28 days of life and only 1 trial, the Trial of Indomethacin Prophylaxis in Preterms (TIPP) that assessed supplemental oxygen use at 36 weeks postmenstrual age (PMA). 2, 8 Treatment with prophylactic indomethacin did not significantly reduce the rates of either BPD outcome, but the point estimates of the relative risks favored the control therapy for both definitions of BPD. 8 
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Bronchopulmonary dysplasia GDB Generic Database NRN Neonatal Research Network PDA Patent ductus arteriosus PMA Postmenstrual age RCTs Randomized controlled trials TIPP Trial of Indomethacin Prophylaxis in Preterms A secondary analysis of TIPP data found that infants randomized to prophylactic indomethacin compared with placebo received a higher fraction of inspired oxygen (FiO2) during the first week of life. 9 Van Overmeire et al 10 demonstrated a similar phenomenon in a randomized trial of early (day 3) vs late (day 7) treatment of echocardiography confirmed PDA. These studies suggest that early treatment with indomethacin may adversely affect early respiratory function and could lead to a small but important increase in the risk for BPD.
It is unlikely that further large placebo-controlled trials of prophylactic indomethacin will be conducted. Therefore, analyses of multicenter observational data may provide the only findings that can help resolve the remaining uncertainty about the risks and benefits of prophylactic indomethacin. To evaluate the potential association between prophylactic indomethacin and the risk for BPD at a PMA of 36 weeks, we conducted an analysis of data collected prospectively for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) Generic Database (GDB).
Methods
The NRN GDB registry (ClinicalTrials.gov: NCT00063063) uses a predefined protocol to prospectively collect maternal and infant demographic and clinical data from birth through hospital discharge, death, or 120 days for all infants with gestational ages between 22 and 28 6/7 weeks or birth weights from 401 to 1000 g born at participating NRN centers. Live born infants who survived the first 12 hours of life and were delivered at the 35 hospitals included in the NRN were evaluated in this analysis. The institutional review board at each study center approved the collection of GDB data. Written or oral parental consent was obtained at 3 centers and a waiver of consent was granted at the remaining centers.
Outcome and Exposure Definitions
The primary study outcome was BPD, defined as the use of supplemental oxygen at 36 weeks PMA among infants who survived to this time point. The secondary outcomes were death before 36 weeks PMA and the composite of death before 36 weeks PMA or BPD. We compared the risks for these outcomes between infants who received prophylactic indomethacin, defined as initiation of indomethacin within the first 24 hours of life, and infants who did not receive prophylactic indomethacin.
Statistical Analyses
Maternal complications of pregnancy and infant characteristics were compared between the infants who were treated with prophylactic indomethacin and those who were not using standard descriptive statistics. Rates of prophylactic indomethacin use at individual hospitals were calculated and reported graphically. The odds of the study outcomes were evaluated using logistic regression. The regression models were adjusted for several prespecified potential confounding variables and those that differed between infants who were and were not treated with prophylactic indomethacin with a P value of <.05 in the bivariate testing. These variables were included as fixed effects and fell into 1 of 3 groups: (1) maternal characteristics (gestational hypertension, multiple gestation pregnancy, rupture of maternal amniotic membranes for longer than 18 hours, treatment with antenatal antibiotics, treatment with antenatal corticosteroids, and cesarean delivery); (2) baseline neonatal characteristics (birth weight and gestational age (as continuous variables), sex, and birth weight <10th percentile determined using the Alexander fetal growth curves) 11 ; and (3) neonatal morbidities occurring in the first 24 hours of life (intubation, receipt of chest compressions, or epinephrine in the delivery room, and mechanical ventilation at 24 hours of life). Hospital was included in all models as a random effect. Data from small hospitals that participated in the NRN as part of a single center and had similar prophylactic indomethacin treatment rates were combined.
We evaluated 5 infant subgroups for potential differences in the association between the use of prophylactic indomethacin and the study outcomes: gestational age (<26 weeks vs ≥26 weeks), birth weight percentile (<10th percentile vs ≥10th percentile), sex, exposure to antenatal corticosteroids (any treatment vs none), and medical or surgical treatment of a PDA after the first 24 hours of life (any treatment vs none). The same logistic regression models described above with the addition of a treatment by subgroup interaction term were used in these analyses. An interaction P value of <.05 was considered to indicate a statistically important subgroup effect. No adjustments for multiple comparisons were made in this exploratory observational study.
Lastly, we performed a post-hoc analysis to assess the risk for the study outcomes associated with the rate of prophylactic indomethacin use at the birth hospital. A 3-level categorical variable with approximately equal numbers of patients per group was added to the multivariable regression models: no use (no infants treated with prophylactic indomethacin during the study period); moderate use (greater than 0% but less than 60% of infants treated with prophylactic indomethacin); and high use (greater than or equal to 60% of infants treated with prophylactic indomethacin). All statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, North Carolina).
Results
Of the 7831 infants included in this analysis recruited between January 1, 2008 and December 31, 2012, 6749 (86.2%) were alive at 36 weeks PMA and were assessed for the primary outcome (Figure 1 ; available at www.jpeds.com). The characteristics of the study population are shown in Table I . Infants who received prophylactic indomethacin compared with those who did not were less mature at birth and were more likely to have a birth weight less than the 10th percentile, to be intubated or have received cardiopulmonary resuscitation in the delivery room, and to be intubated at 24 hours of life ( Table I) . Treatment with prophylactic indomethacin was associated with Volume 186 • July 2017 lower rates of subsequent medical or surgical therapy for a PDA (21.0% vs 36.1%, P < .001).
The proportion of infants treated with prophylactic indomethacin at each of the 35 participating hospitals ranged from 0% to 98% (Figure 2 ). The median treatment rate across all hospitals was 12%. Twelve hospitals (34.3%) did not prescribe prophylactic indomethacin to any infants included in this analysis.
Primary Outcome
The rates of BPD among infants who survived to 36 weeks PMA were similar among those who received prophylactic indomethacin and those who did not (44.8% vs 44.3%, P = .72). After adjustment for hospital and 11 maternal and neonatal characteristics, the OR for BPD associated with treatment with prophylactic indomethacin was 0.89 (95% CI 0.72-1.10; Figure 3 ). There was no evidence of differential treatment effects on the risk for BPD for any of the 5 infant subgroups (Figure 3 ).
Secondary Outcomes
In contrast to BPD, the rates of death before 36 weeks PMA (17.2% vs 12.2%, P < .001), and the composite of death before 36 weeks PMA or BPD (54.3% vs 51.1%, P = .008) were higher 
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Volume 186 among the infants who received prophylactic indomethacin compared with untreated infants. However, after adjustment for potential confounding variables, treatment with prophylactic indomethacin was not associated with an increased risk of either study outcome (Table II) . There was evidence of two subgroup effects for the outcome of death before 36 weeks PMA (Table II) . Prophylactic indomethacin was associated with lower odds of death among infants with birth weights ≥10th percentile but not among those born <10th percentile (interaction P = .007). The odds of death were also lower for infants treated with prophylactic indomethacin among those who did not receive therapy for a PDA after the first 24 hours life (interaction P = .009). Lastly, there was weak evidence of a potential subgroup effect for sex (interaction P = .09), with lower odds of death among female infants but not male infants who were treated with prophylactic indomethacin. There was no evidence of heterogeneity of effects for the composite outcome of death before 36 weeks PMA or BPD (Table II) .
Post-Hoc Analysis by Hospital Use of Prophylactic Indomethacin
BPD was less common among survivors to 36 weeks PMA cared for in a hospital with high prophylactic indomethacin treatment rates. After adjustment for potential confounders, delivery at a high use hospital compared with a no use hospital was associated with lower risk for BPD (OR 0.31, 95% CI 0.14-0.69). The difference was not statistically significant for the Figure 3 . BPD among survivors to 36 weeks PMA. Unadjusted rates and risk aORs for the full cohort and 5 infant subgroups are shown. n indicates the number of infants with the outcome and N indicates the total number of infants in each group. ORs were determined with adjustment for hospital as a random effect and birth weight, gestational age, sex, birth weight <10th percentile for sex and gestational age, maternal gestational hypertension, antenatal antibiotic exposure, antenatal corticosteroid exposure, rupture of amniotic membranes for greater than 18 hours, cesarean delivery, intubation or cardiopulmonary resuscitation in the delivery room, and invasive mechanical ventilation at 24 hours of life as fixed effects.
comparison of moderate use with no use hospitals (OR 0.60, 95% CI 0.29-1.22). The frequency of death before 36 weeks PMA was similar when compared based on the hospital rate of prophylactic indomethacin use. However, rates of the composite outcome of death before 36 weeks PMA or BPD were lower at high use hospitals. In the adjusted analysis, only birth at a high use compared with no use hospital was associated with lower odds of death or BPD (high vs none OR 0.35, 95% CI 0.18-0.71; moderate vs none OR 0.58, 95% CI 0.31-1.09).
Discussion
In this large, multicenter cohort of extremely preterm infants, the use of prophylactic indomethacin was not associated with either increased or decreased risks for BPD, death before 36 weeks PMA, or the combined outcome of death or BPD. As with all observational studies, these findings should be interpreted with appropriate caution. This study design cannot establish causality, only plausible associations. Moreover, in multicenter nonrandomized studies such as this, center is often a strong predictor of both treatment and outcome. 12, 13 To account for potential confounding by center, we included birth hospital as a random effect in all models. 12 However, residual confounding by hospital may persist. Finally, we are only able to adjust for measured clinical covariates and cannot account for potentially important but unknown factors that may differentially affect use of prophylactic indomethacin or outcome risk. Despite these limitations, this retrospective study of prospectively collected data provides contemporary results suggesting that prophylactic indomethacin use is not associated with either increased or decreased risk for BPD at 36 weeks PMA in extremely preterm infants.
Our finding of similar BPD rates among infants who received prophylactic indomethacin compared with those who did not is consistent with data from previous randomized controlled trials (RCTs). 2, 8 We observed this lack of an association between indomethacin prophylaxis and the risk for BPD despite a reduction in the frequency of later treatment for a PDA from 36% to 21%. Although the direction of effect in the present analysis favored prophylactic indomethacin for n indicates the number of infants with the outcome and N indicates the total number of infants in each group. *Model adjusted for hospital as a random affect and birth weight, gestational age, sex, birth weight <10th percentile for sex and gestational age, maternal gestational hypertension, antenatal antibiotic exposure, antenatal corticosteroid exposure, rupture of amniotic membranes for greater than 18 hours, delivery by cesarean, intubation or cardiopulmonary resuscitation in the delivery room, and invasive mechanical ventilation at 24 hours of life as fixed effects.
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Volume 186 prevention of BPD while the previous studies did not, 2,8 the interpretation of the trial and observational data is consistent. Prophylactic indomethacin is unlikely to have any beneficial or harmful effects on the risk for BPD among extremely preterm infants and if present, any effect is likely to be small.
The reasons for the apparent lack of a beneficial effect of prophylactic indomethacin on the risk for BPD are unclear. Although persistence of a PDA is associated with the development of BPD, pharmacologic treatment of a PDA may not reduce this risk. It is also possible that the beneficial effects of ductal closure with prophylactic indomethacin may be offset by adverse drug effects such as water retention because of impaired renal function or direct toxicity to the lung. 2, [14] [15] [16] In contrast to BPD, the unadjusted rates of death before 36 weeks PMA and the composite outcome of death or BPD were higher among the infants who received prophylactic indomethacin compared with those who did not. However, when these associations were evaluated in the multivariable models, the point estimates for the ORs favored treatment with prophylactic indomethacin but with CIs that included the point of equivalence. A meta-analysis of RCTs that assessed death before hospital discharge also found a nonsignificant reduction in the risk of death among infants treated with prophylactic indomethacin compared with placebo.
2 However, when all deaths occurring before the latest follow-up were considered, the potential benefit was no longer present. 2 We found evidence of 2 subgroup effects among the 15 subgroup analyses we conducted. Prophylactic indomethacin compared with no therapy was associated with lower odds of death among infants with birth weights above the 10th percentile and among those who did not undergo medical or surgical therapy for a PDA after the first day of life. This latter finding suggests that prophylactic indomethacin may protect against mortality among infants who do not develop a symptomatic PDA. We also found weak evidence of heterogeneity of treatment effects based on sex, with lower risk of death among female but not male infants who received prophylactic indomethacin.
Two post-hoc analyses of TIPP data evaluated potential subgroup effects for mortality and neurodevelopmental outcomes; BPD was not assessed. 17, 18 Similar to our findings, TIPP investigators found no difference in the risk of death with prophylactic indomethacin compared with placebo based on a full course vs partial course or no treatment with antenatal corticosteroids. 18 TIPP also found a possible subgroup effect for mortality by sex (interaction P value = .054). 17 However, in contrast to our results, the risk of death was increased for female infants who were treated with prophylactic indomethacin compared with placebo and was no different for male infants. 17 Although the pitfalls of subgroup analyses are well described, when they are prespecified and assessed with appropriate interaction testing, they can generate important hypotheses for future prospective studies. 19, 20 An additional consideration with subgroup analyses is the possibility of type I error because of multiple testing. We assessed the risk associated with prophylactic indomethacin for 3 outcomes in 5 subgroups (15 total comparisons). Based on this number of tests, the probability of finding 1 or more nominally significant interaction terms (P = .05) is approximately 54%. 20 The probability of 2 or more subgroup effects being identified by chance is 17%. 20 Finally, our post-hoc analysis suggested that delivery in a hospital in which at least 60% of extremely preterm infants received prophylactic indomethacin compared with one where no infants were treated was associated with reduced risk for BPD among survivors to 36 weeks PMA and the composite outcome of death before 36 weeks PMA or BPD. Although it is tempting to infer from this finding that high use of prophylactic indomethacin may reduce BPD risk, caution should be used when interpreting these results. First, residual confounding by unmeasured differences in patient characteristics, clinical care, and other hospital factors cannot be excluded. Second, these findings are in contrast to and should not supersede the results of the primary analysis of this observational study or the available randomized trial data showing no benefit with prophylactic indomethacin for prevention of BPD. 2, 8 In conclusion, this study examined the possible association between prophylactic indomethacin and BPD. In this contemporary cohort of extremely preterm infants, we found no evidence that prophylactic indomethacin was associated with increased or decreased risks for BPD, death, or the combined outcome of death or BPD. The use of prophylactic indomethacin was associated with decreased mortality in 2 subgroups of infants. However, these findings require confirmation in prospective studies. ■ We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. I nfantile hypertrophic pyloric stenosis has been described in medical journals since the 18th century and it is considered to be the most common cause of intestinal obstruction in infancy. 1 Fifty years ago, Shuman et al reported a series of 204 infants with proven infantile hypertrophic pyloric stenosis evaluated between 1960 and 1966. The authors reviewed the classical roentgenological signs: the "string," the "beak," "shoulder," "double-track," and the "tit" signs. All are nicely portrayed in this 50-year-old paper with visual examples that help to understand the anatomy and pathophysiology of a condition widely known by pediatricians.
Nowadays, in an increasing number of hospitals and clinical teaching environments, these classical signs noted via upper gastrointestinal contrast radiology for the diagnosis of infantile hypertrophic pyloric stenosis are more of historical value. Ultrasound imaging is an increasingly used test owing to its availability, feasibility, and attractive advantages such as zero radiation exposure, less time consuming, and with greater numbers of experienced examiners available. 2 Notwithstanding the passage of time, one recommendation that does not seem to be affected by the years is the use of experience and skills in everyday clinical practice. In other words, experienced clinicians palpating a pyloric "olive" in an infant 3 to 6 weeks of age with progressive nonbilious projectile vomiting and peristaltic waves should be confident enough about the diagnosis and hence should avoid the use of the imaging tests available. 
